Results 211 to 220 of about 125,005 (308)

Junctional sensitivity and atrophy progression rate of geographic atrophy secondary to age‐related macular degeneration

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To determine the relationship between the baseline junctional retinal sensitivity measured with microperimetry and the atrophy progression rate in eyes with geographic atrophy (GA) secondary to age‐related macular degeneration. Methods In this prospective cohort study, patients with GA were examined with fundus autofluorescence (FAF ...
Alexander Kai Thomsen   +5 more
wiley   +1 more source

Glucose-Powered Ultrasmall Chemotactic Nanorobots for Retinal Degeneration Treatment. [PDF]

open access: yesJ Am Chem Soc
Ju X   +4 more
europepmc   +1 more source

Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration (RISE‐AMD): Safety data

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan   +12 more
wiley   +1 more source

Real‐world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider   +7 more
wiley   +1 more source

Impact of delayed appointments on treatment outcomes in neovascular macular degeneration

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola   +3 more
wiley   +1 more source

New perspectives on VEGF signalling in Alzheimer's disease

open access: yesBrain Pathology, EarlyView.
Emery et al. bring together findings from recent multi‐omic studies, including single‐cell mRNA analysis of human post‐mortem brain tissue, and proteomic analysis of matched CSF and blood samples in large clinical studies. The authors present evidence of the involvement of altered VEGF signalling in vascular and immune dysfunction and neurodegeneration
Cherelle E. G. Emery   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy